Decongestion in acute heart failure
Key result
Serelaxin reduces all-cause mortality ~37% vs placebo in acute heart failure.
- HR 0.63
- 95% CI 0.43-0.93
Why the study?
What are the appropriate decongestion strategies for patients with acute heart failure?
Population
Patients with acute heart failure and congestion
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Serelaxin may aid acute HF decongestion; leaves open need for confirmatory RCTs before practice change.
Key Points
- To summarize the benefit and risk profiles of various decongestion strategies and provide practical clinical guidance for managing fluid overload in acute heart failure.
- Synthesized consensus discussions and trial evidence from the 9th Global Cardio Vascular Clinical Trialists Forum in Paris (2012).
- Evaluated pharmacological interventions (intravenous diuretics, vasodilators, vasopressin antagonists, mineralocorticoid receptor antagonists) and mechanical fluid removal (ultrafiltration).
- High-dose intravenous diuretics combined with vasodilators (when blood pressure permits) serve as the primary initial strategy for dyspnea relief.
- Dual nephron blockade with thiazides or natriuretic doses of mineralocorticoid receptor antagonists effectively manages diuretic resistance, while vasopressin antagonists promote aquaresis.
- Ultrafiltration provides a non-pharmacological alternative when diuretic strategies fail, but requires cautious implementation to avoid worsening renal function.
Structured PICO
What are the appropriate decongestion strategies for patients with acute heart failure?
P
Population
Patients with acute heart failure and congestion
I
Intervention
Decongestion strategies including diuretics, vasodilators, ultrafiltration, vasopressin antagonists, mineralocorticoid receptor antagonists, gut sequesterants, and serelaxin
Main Result
Effect estimate: HR 0.63 (95% CI 0.43-0.93)
This review outlines an evidence-based approach to decongestion in acute heart failure, emphasizing high-dose IV diuretics and vasodilators as first-line therapy.
Cite This Study
Mentz et al. (2014) studied acute heart failure. serelaxin vs. placebo was evaluated on dyspnoea improvement and all-cause mortality at 180 days (HR 0.63, 95% CI 0.43-0.93). Serelaxin significantly reduced all-cause mortality by 37% compared to placebo in patients with acute heart failure.